GCA
EBS icon

Gideon Capital Advisors’s Emergent Biosolutions EBS Stock Holding History

Gideon Capital Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-9,619
Closed -$570K – 412
2018
Q4 		$570K Buy
+9,619
New +$620K 0.23% 129

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Gideon Capital Advisors's EBS Position: Q1 2019 in Review

Gideon Capital Advisors sold out of Emergent Biosolutions (EBS) in Q1 2019, closing a stake of 9,619 shares — an estimated $570K sold.

Gideon Capital Advisors first reported a position in EBS in Q4 2018 and held it in 1 quarter. The position peaked at $570K in Q4 2018. 272 funds tracked by Wall St. Rank hold EBS as of Q1 2019.

  • Gideon Capital Advisors reported no remaining Emergent Biosolutions position as of Q1 2019 after selling out during the quarter.
  • Gideon Capital Advisors sold 9,619 Emergent Biosolutions shares in Q1 2019, an estimated $570K.
  • Gideon Capital Advisors first reported a position in Emergent Biosolutions in Q4 2018 and held it in 1 quarter.
  • Gideon Capital Advisors's Emergent Biosolutions position peaked at $570K in Q4 2018.
  • 272 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2019.

Based on Gideon Capital Advisors's 13F filing for Q1 2019, filed 14 May 2019.